



Marinus Pharmaceuticals  
Investor Relations Department  
170 N. Radnor Chester Road,  
Suite 250  
Radnor, PA 19087-5279  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: MRNS

Last Trade:	4.36
Trade Time:	4:00 PM ET Sep 21, 2017
Change:	0.20 <span style="color: green;">▲</span> (+4.808%)
Day Range	4.00 - 4.52
52-Week Range	0.82 - 5.44
Volume	1,809,478


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Sep 21, 2017*  
[Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference](#)
- Sep 19, 2017*  
[Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares](#)
- Sep 15, 2017*  
[Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock](#)
- Sep 14, 2017*  
[Marinus Pharmaceuticals Announces Public Offering of Common Stock](#)
- Sep 11, 2017*  
[Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone](#)

## Upcoming Events [\[ View all \]](#)

- Sep 25–27, 2017*  
[Cantor Fitzgerald's Global Healthcare Conference](#)
- Oct 4–7, 2017*  
[Child Neurology Society](#)
- Mar 13, 2017*  
[Annual Report \(10-K\)](#)
- Mar 16, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*  
[Quarterly Report \(10-Q\)](#)

## Financials & Filings [\[ View all \]](#)

[Second Quarter Financial Results](#)